Gene | Aptamer ID | Protein | log2FC | p Value | FDR adjusted p Value |
---|---|---|---|---|---|
Higher levels in participants with IPF versus controls | |||||
 PGAM1 | 3896–5 | Phosphoglycerate mutase 1 | 1.260 | 9.00E-08 | 9.24E-07 |
 GPD1 | 11,081–1 | Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic | 1.224 | 4.95E-19 | 3.08E-17 |
 THBS1 | 3474–19 | Thrombospondin-1 | 1.203 | 1.46E-16 | 6.55E-15 |
 VWF | 3050–7 | von Willebrand factor | 1.136 | 3.68E-32 | 1.20E-29 |
 CCL17 | 3519–3 | C-C motif chemokine 17 | 1.053 | 2.38E-16 | 1.03E-14 |
 BPI | 4126–22 | Bactericidal permeability-increasing protein | 1.031 | 7.26E-15 | 2.37E-13 |
 OLR1 | 3636–37 | Oxidised low-density lipoprotein receptor 1 | 0.929 | 4.84E-32 | 1.26E-29 |
 CAPG | 4968–50 | Macrophage-capping protein | 0.882 | 1.09E-28 | 1.43E-26 |
 SPARC | 3043–49 | SPARC | 0.869 | 3.13E-15 | 1.13E-13 |
 FN1 | 4131–72 | Fibronectin | 0.864 | 1.19E-30 | 2.59E-28 |
 PF4 | 2697–7 | Platelet factor 4 | 0.853 | 7.84E-08 | 8.32E-07 |
 PPBP | 4544–4 | Connective tissue-activating peptide III | 0.850 | 2.74E-08 | 3.26E-07 |
 PPBP | 2790–54 | Neutrophil-activating peptide 2 | 0.844 | 3.23E-08 | 3.73E-07 |
 ICAM5 | 5124–69 | Intercellular adhesion molecule 5 | 0.841 | 4.10E-34 | 1.78E-31 |
 CXCL13 | 3487–32 | C-X-C motif chemokine 13 | 0.834 | 1.63E-15 | 6.27E-14 |
 PGD | 4187–49 | 6-phosphogluconate dehydrogenase, decarboxylating | 0.833 | 7.64E-07 | 6.39E-06 |
 C1R | 3285–23 | Complement C1r subcomponent | 0.825 | 3.39E-29 | 5.49E-27 |
 HIST1H1C | 2987–37 | Histone H1.2 | 0.808 | 1.58E-07 | 1.56E-06 |
 MMP9 | 2579–17 | Matrix metalloproteinase-9 | 0.792 | 4.49E-16 | 1.83E-14 |
 SFTPD | 4414–69 | Pulmonary surfactant-associated protein D | 0.789 | 1.75E-08 | 2.20E-07 |
 GDF15 | 4374–45 | Growth/differentiation factor 15 | 0.782 | 2.32E-28 | 2.75E-26 |
 S100A9 | 5339–49 | Protein S100-A9 | 0.778 | 9.08E-18 | 4.74E-16 |
 FN1 | 3434–34 | Fibronectin fragment 3 | 0.770 | 3.78E-29 | 5.49E-27 |
 PDGFB | 4149–8 | Platelet-derived growth factor subunit B | 0.768 | 7.67E-08 | 8.25E-07 |
 CCL18 | 3044–3 | C-C motif chemokine 18 | 0.734 | 2.31E-29 | 4.31E-27 |
 ANXA6 | 5335–73 | Annexin A6 | 0.725 | 3.36E-09 | 4.82E-08 |
 MMP1 | 4924–32 | Matrix metalloproteinase-1 | 0.712 | 3.92E-11 | 8.25E-10 |
 TIMP3 | 2480–58 | Metalloproteinase inhibitor 3 | 0.690 | 4.04E-10 | 7.32E-09 |
 VAV1 | 5275–28 | Proto-oncogene vav | 0.687 | 8.31E-05 | 4.15E-04 |
 HNRNPA2B1 | 5351–52 | Heterogeneous nuclear ribonucleoproteins A2/B1 | 0.683 | 2.27E-12 | 5.69E-11 |
 PDGFA | 4499–21 | Platelet-derived growth factor subunit A | 0.665 | 3.05E-08 | 3.55E-07 |
 APP | 3171–57 | Amyloid-beta A4 protein | 0.662 | 1.34E-11 | 2.97E-10 |
 S100A6 | 13,090–17 | Protein S100-A6 | 0.625 | 4.47E-14 | 1.33E-12 |
 CCL5 | 5480–49 | C-C motif chemokine 5 | 0.614 | 3.43E-07 | 3.15E-06 |
 C4A C4B | 2182–54 | Complement C4A and C4B | 0.604 | 1.13E-08 | 1.49E-07 |
 CCL22 | 3508–78 | C-C motif chemokine 22 | 0.599 | 6.96E-18 | 3.95E-16 |
 HK2 | 13,130–150 | Hexokinase-2 | 0.592 | 2.22E-09 | 3.35E-08 |
Lower levels in participants with IPF versus controls | |||||
 MMP3 | 2788–55 | Stromelysin-1 | −1.343 | 2.77E-36 | 1.81E-33 |
 CKB CKM | 3714–49 | Creatine kinase B-type; Creatine kinase M-type | −1.325 | 4.95E-22 | 4.04E-20 |
 ADSL | 5023–23 | Adenylosuccinate lyase | −1.126 | 2.70E-26 | 2.93E-24 |
 SHH | 2743–5 | Sonic hedgehog protein | −0.852 | 7.35E-26 | 7.38E-24 |
 CA6 | 3352–80 | Carbonic anhydrase 6 | −0.778 | 2.15E-15 | 8.01E-14 |
 AGER | 4125–52 | Advanced glycosylation end product-specific receptor | −0.770 | 5.74E-20 | 3.74E-18 |
 HSPB1 | 11,103–24 | Heat shock protein beta-1 | −0.734 | 1.46E-05 | 9.18E-05 |
 TFF1 | 9185–15 | Trefoil factor 1 | −0.708 | 1.20E-12 | 3.20E-11 |
 PRKCA | 2644–11 | Protein kinase C alpha type | −0.695 | 3.68E-04 | 1.54E-03 |
 PRKACA | 3466–8 | cAMP-dependent protein kinase catalytic subunit alpha | −0.590 | 7.02E-05 | 3.63E-04 |